MedPath

A randomised, double blind, placebo controlled study to Assess The Effect of Antibiotic Therapy on Chronic Rejection in Human Lung Transplantation - Azithromycin Study

Conditions
Post Lung Transplantation Chronic Rejection identified as bronchiolitis obliterans syndrome (BOS)
Registration Number
EUCTR2006-000485-36-GB
Lead Sponsor
ewcastle upon Tyne Hospitals NHS Trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
64
Inclusion Criteria

1. Lung transplant recipient
2. Male or Female
3. Age 16 years or over
4. Airflow limitation – FEV1 < 80% maximum recorded post transplant
5. Ability to give Informed Consent

Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Airflow limitation caused by other clinical problems (e.g clinical infection)
2. Known hypersensitivity to Azithromycin or any of the macrolide antibiotics
3. Participation in another drug related trial within 90days
4. Severe renal or hepatic impairment
5. Use of concomitant medication that would interact with azithromycin

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath